

## **Product datasheet for TA335175**

## **RFX5 Rabbit Polyclonal Antibody**

## **Product data:**

**Product Type:** Primary Antibodies

Applications: WB

Recommended Dilution: WB

Reactivity: Human

Host: Rabbit

**Isotype:** IgG

Clonality: Polyclonal

**Immunogen:** The immunogen for anti-RFX5 antibody: synthetic peptide directed towards the N terminal of

human RFX5. Synthetic peptide located within the following region: MAEDEPDAKSPKTGGRAPPGGAEAGEPTTLLQRLRGTISKAVQNKVEGIL

Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2%

sucrose.

Note that this product is shipped as lyophilized powder to China customers.

**Purification:** Protein A purified

Conjugation: Unconjugated

**Store** at -20°C as received.

**Stability:** Stable for 12 months from date of receipt.

Predicted Protein Size: 68 kDa

**Gene Name:** regulatory factor X5

Database Link: NP 001020774

Entrez Gene 5993 Human

P48382



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



Background:

RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. RFX is a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNAbinding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.

Synonyms: 5; 5 (influences HLA class II expression); OTTHUMP0000082795; OTTHUMP00000196318;

regulatory factor X


**Note:** Immunogen Sequence Homology: Human: 100%; Dog: 86%; Pig: 86%; Horse: 86%; Rabbit:

86%; Rat: 79%; Guinea pig: 79%

**Protein Families:** Transcription Factors

**Protein Pathways:** Antigen processing and presentation, Primary immunodeficiency

## **Product images:**



WB Suggested Anti-RFX5 Antibody Titration: 2.5 ug/ml; ELISA Titer: 1: 1562500; Positive Control: Transfected 293T